Literature DB >> 19913656

Tourette syndrome and comorbid early-onset schizophrenia.

Jacob Kerbeshian1, Chun-Zi Peng, Larry Burd.   

Abstract

OBJECTIVE: A study of the shared phenomenology between Tourette syndrome (TS) and schizophrenia.
METHOD: An illustrative case report is presented. We used a chart review of 399 clinically ascertained patients with TS to identify 10 cases meeting criteria for schizophrenia. From our 10 patients, salient clinical characteristics were then tabulated. We then extracted similar clinical characteristics from a previously published series of patients with comorbid TS and schizophrenia in order to combine cases and allow for a comparison between childhood-onset schizophrenia (COS), adolescent-onset schizophrenia (AdolOS), and adult-onset schizophrenia (AduOS) cases in these groups.
RESULTS: We found 10 cases of schizophrenia (all were males) in the 399 TS patients for a prevalence rate of 2.5% (95% CI 0.96-4.04). Mean age of tic onset for TS diagnostic criteria ranged from 2-14 years with a mean of 8.2 years. The mean age of diagnosis for schizophrenia was 14.2 (range 9-23 years). We found six cases of schizophrenia with onset of positive psychotic symptoms by 13 years of age, two cases with onset after 13 years of age and before 18 years of age, and two cases with onset after 18 years of age. Attention deficit hyperactivity disorder was present at a higher rate (70%) than one would expect in a clinically ascertained group of patients with TS. Comparison between COS, AdolOS and AduOS in our pooled cases noted a sex bias skewed toward males. Catatonic symptoms may be more likely in child or adolescent onset cases and negative symptoms more likely in AduOS cases.
CONCLUSIONS: The 2.5% prevalence of schizophrenia in our TS sample exceeds the 1% expected rate of schizophrenia in the general population (chi-square=9.14; P=.0025). The six cases of COS (before 13 years of age) exceeds the expected rate of 1-2 per 100,000 (chi-square=4499; P=.0001). The 752-fold increase in observed rates of comorbid TS and COS over expected rates suggests a role for unknown common underlying etiologic factors. Based on clinical features, patients with TS and comorbid COS, AdolOS, or AduOS do not have different conditions. We conclude with suggestions for further research.

Entities:  

Mesh:

Year:  2009        PMID: 19913656     DOI: 10.1016/j.jpsychores.2009.08.002

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  8 in total

Review 1.  MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction.

Authors:  Bin Xu; Pei-Ken Hsu; Maria Karayiorgou; Joseph A Gogos
Journal:  Neurobiol Dis       Date:  2012-03-03       Impact factor: 5.996

2.  Diagnostic and statistical manual of mental disorders.

Authors:  Vijay A Mittal; Elaine F Walker
Journal:  Psychiatry Res       Date:  2011-07-07       Impact factor: 3.222

Review 3.  MicroRNAs in psychiatric and neurodevelopmental disorders.

Authors:  Bin Xu; Maria Karayiorgou; Joseph A Gogos
Journal:  Brain Res       Date:  2010-04-10       Impact factor: 3.252

4.  Versatility of the mouse reversal/set-shifting test: effects of topiramate and sex.

Authors:  Gregory B Bissonette; Michelle D Lande; Gabriela J Martins; Elizabeth M Powell
Journal:  Physiol Behav       Date:  2012-06-04

Review 5.  Nosology and Phenomenology of Psychosis in Movement Disorders.

Authors:  Malco Rossi; Nicole Farcy; Sergio E Starkstein; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2020-01-07

6.  Language evolution: examining the link between cross-modality and aggression through the lens of disorders.

Authors:  Antonio Benítez-Burraco; Ljiljana Progovac
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2021-03-22       Impact factor: 6.237

7.  Tourette's syndrome and schizophrenia: About a case report.

Authors:  Hentati Salma; Sellami Rim; Abida Imen; Masmoudi Jaweher
Journal:  Indian J Psychiatry       Date:  2017 Oct-Dec       Impact factor: 1.759

8.  Clerodendrum inerme Leaf Extract Alleviates Animal Behaviors, Hyperlocomotion, and Prepulse Inhibition Disruptions, Mimicking Tourette Syndrome and Schizophrenia.

Authors:  Hon-Lie Chen; Hsin-Jung Lee; Wei-Jan Huang; Jui-Feng Chou; Pi-Chuan Fan; Jung-Chieh Du; Yuan-Ling Ku; Lih-Chu Chiou
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-15       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.